Latest Breaking News On - வாரம் கட்டம் - Page 1 : comparemela.com

Alkermes Presents New Data From Psychiatry Portfolio at Virtual 2021 Congress of the Schizophrenia International Research Society - New Exploratory Analyses Presented From ENLIGHTEN-2 Study of LYBALVI™ in Patients With Schizophrenia - News provided by Share this article Share this article DUBLIN, April 20, 2021 /PRNewswire/  Alkermes plc (Nasdaq: ALKS) today announced the presentation of new research from its psychiatry portfolio at the 2021 Congress of the Schizophrenia International Research Society (SIRS), taking place virtually April 17-21, 2021. The company s presentations included new exploratory analyses from the phase 3 ENLIGHTEN-2 study of olanzapine/samidorphan (LYBALVI™), formerly referred to as ALKS 3831, including: Results from prespecified subgroup analyses evaluating olanzapine/samidorphan s effect on weight gain across several patient subgroups, including those known to be at higher risk for weight gain with olanzapine, based on sex, race, age and ba

United statesCraig hopkinsonMarisa borgasanoAripiprazole lauroxilSandy coombsExchange commissionSchizophrenia international research societyAlkermes pharma irelandResearch developmentExecutive vice presidentChief medical officerPatients knownIncreased riskWeight gain with olanzapine treatmentWith olanzapineResults from